Alex Goldberg

NASDAQ Gainers Watch List: Cell Therapeutics, Inc. (NASDAQ:CTIC) and Ares Capital Corporation (NASDAQ:ARCC) Added to Equity Profile Report's NASDAQ Gainers Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 12/27/2013 -- -- Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding Cell Therapeutics, Inc. (NASDAQ:CTIC) and Ares Capital Corporation (NASDAQ:ARCC).

Cell Therapeutics, Inc. (NASDAQ:CTIC) a company that acquires, develops, and commercializes treatments for cancer closed up in its previous session (+1.60%) on 1,404,062 shares traded. Cell Therapeutics, Inc. (NASDAQ:CTIC) is currently up (+98.97%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about Cell Therapeutics, Inc. (NASDAQ:CTIC)

Ares Capital Corporation (NASDAQ:ARCC) a company that specializes in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies closed up in its previous session (+0.06%) on 1,356,792 shares traded. Ares Capital Corporation (NASDAQ:ARCC) is currently up (+9.6%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about Ares Capital Corporation (NASDAQ:ARCC)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com